U.S. Department of Justice, Office of Justice Programs, Contracts Branch, 633 Indiana Avenue, N.W., Room 542, Washington, D.C. 20531

Q -- LABORATORY TESTING FOR THE ADAM PROGRAM SOL OJP-97-R-010 DUE 061697 POC Carrie F. Causey, Contracting Officer (202) 616-1901 or Robyn D. Towles, Chief Contracting Officer (202) 616-9226 The Office of Justice Programs, National Institute of Justice (NIJ) has a four year (base year plus three option years) requirement for a contractor to provide personnel, equipment, and materials necessary to support NIJ's Arrestee Drug Abuse Monitoring program by processing urine specimens that are generated by this program,and work directly with the ADAM Data Collection Contractor (DCC). The ADAM DCC will collaborate with NIJ on the design, implementation, and management of the ADAM program. The ADAM program will operate in a minimum of 23 sites and a maximum of 35 sites throughout the United States in the Base Year of the contract, expand to a maximum of 50 sites in Option Year 1, grow to a maximum of 75 sites in contract Option Year 2, and operate in a maximum of 75 sites through Option Year 3. Laboratories must be Health and Human Services (HHS) certified for drug testing to be eligible under this contract. The contractor shall follow the guidelines that are current operating procedures and any modified procedures in place for the Drug Use Forecasting (DUF) program. The anticipated ADAM data collection procedures are as follows: In each site, for approximately 2 weeks every quarter, voluntary and anonymous urine specimens, interview data, and on occasion, additional bioassays will be collected from arrestees. Data shall be collected from adult male, adult female, juvenile female, and juvenile male arrestees/detainees. Urine specimens shall be screened for a minimum of ten drugs (Amphetamines, Barbiturates, Cocaine, Propoxyphene, Methadone, Methaqualone, Opiates, PCP, Cannabinoids, and Benzodiazepines). Other drugs may be substituted with the appropriate cutoff levels determined at the time the substitutions are made. The contractor shall analyze a minimum of 115,200 and a maximum of 500,000 urine specimens for the above drugs over the life of the contract. All specimens screened positive for amphetamines (approximately 10% annually) shall be confirmed by GC using a cutoff 300 NG/ML. All specimens screened positive for benzodiazepines (approximately 5% annually) shall be confirmed by GC using an appropriate cutoff to be determined. Over-the-counter (OTC) drug positives shall also be reported for each specimen tested by GC for amphetamines. The day-to-day reporting issues shall be coordinated with the DCC contractor. The number of days required for urinalysis reporting shall not exceed 15 working days. It is anticipated that this will be a Performance Based, Firm-Fixed Price contract. Proposals will be evaluated using the best value approach. Interested firms shall submit their requests for the RFP in writing not later than 15 days after the publication of this announcement to the address specified above. Facsimile requests are accepted. The fax number is (202) 307-0086. Telephone requests will not be honored. (0122)

Loren Data Corp. http://www.ld.com (SYN# 0053 19970506\Q-0001.SOL)